Pivotal Study to Evaluate the Safety and Efficacy of GelrinC for Treatment of Cartilage Defects
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - 50 |
Updated: | 3/16/2019 |
Start Date: | November 14, 2017 |
End Date: | November 2023 |
Contact: | Jonathan Elsner, PhD |
Email: | jelsner@regentis.co.il |
Phone: | 609 557 7412 |
A Prospective, Open-Label, Multicenter Pivotal Study to Evaluate the Safety and Efficacy of GelrinC® for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle: A Comparison to Historical Control Microfracture
Multicenter, open-label, controlled, non-randomized, double arm trial with a prospective
treatment arm (GelrinC). This study compares the efficacy and safety of GelrinC to a
historical control arm (microfracture) in the treatment of cartilage defects in the knee.
treatment arm (GelrinC). This study compares the efficacy and safety of GelrinC to a
historical control arm (microfracture) in the treatment of cartilage defects in the knee.
Main Inclusion Criteria:
- Age between 18 and 50.
- Single contained symptomatic lesion located on the femoral condyle of the femur graded
as ICRS III or IV with less than 5 mm of bone loss below the subchondral plate.
- Lesion size between 1 and 5 cm2 post debridement, less than or equal to 2.5 cm in
diameter.
- BMI ≤35
- Contralateral knee is asymptomatic, stable, fully functional and not medically
treated.
Main Exclusion Criteria:
- Presence of an additional grade III or IV symptomatic lesion.
- Recent Osteochondritis Dissecans within 1 year of baseline visit.
- Untreated ACL and/or PCL deficiency or Complex ligamentous instability of the knee.
- Patient is excluded if presenting untreated current meniscal tear or if previous
menisci resection was within the last 6 months.
- Previous tendon repair or ligament reconstruction within the last 6 months.
- Failed Mosaicplasty or ACI or MACI or any other cartilage repair product.
- Microfracture performed less than 1 year before baseline visit.
We found this trial at
13
sites
Chicago, Illinois 60612
Principal Investigator: Adam Yanke, MD
Phone: 833-430-8686
Click here to add this to my saved trials
Altoona, Pennsylvania 16602
Principal Investigator: Robert J Singer, DO
Phone: 833-430-8686
Click here to add this to my saved trials
Bloomington, Minnesota 55431
Principal Investigator: Brad Nelson, MD
Phone: 833-430-8686
Click here to add this to my saved trials
Bozeman, Montana 59718
Principal Investigator: Timothy O'Brien, MD
Phone: 833-430-8686
Click here to add this to my saved trials
Denver, Colorado 80210
Principal Investigator: Rachel Frank, MD
Phone: 833-430-8686
Click here to add this to my saved trials
Fort Lauderdale, Florida 33316
Principal Investigator: Kevin Shrock, MD
Phone: 833-430-8686
Click here to add this to my saved trials
Click here to add this to my saved trials
La Mesa, California 91942
Principal Investigator: Scott Hacker, MD
Phone: 833-430-8686
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Orlando, Florida 32822
Principal Investigator: Sean McFadden, MD
Phone: 833-430-8686
Click here to add this to my saved trials
Salisbury, Maryland 21804
Principal Investigator: Jason Scopp, MD
Phone: 833-430-8686
Click here to add this to my saved trials
Savannah, Georgia 31405
Principal Investigator: David Palmer, MD
Phone: 833-430-8686
Click here to add this to my saved trials